title: Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
abstract: OBJECTIVE
  Glycaemic control is critical to prevent diabetic complications and mortality. This 6-month, open-label, observational study assessed the efficacy and safety of switching Japanese patients with type 2 diabetes from neutral protamine Hagedorn (NPH) insulin to insulin detemir.
  
  
  METHODS
  Patients with type 2 diabetes (n = 126) receiving basal-bolus insulin therapy with NPH insulin plus rapid-acting insulin analogues were recruited. NPH insulin was replaced with insulin detemir for 6 months. Glycosylated haemoglobin (HbA(1c)), fasting plasma glucose  (FPG), daily glucose levels and hypoglycaemia were monitored. Nocturnal quality of life was assessed by insulin therapy related quality of life at night questionnaire.
  
  
  RESULTS
  HbA(1c), FPG and body weight were all significantly reduced after treatment with insulin detemir for 6 months,  without increasing severe hypoglycaemia. Insulin dose increased significantly over the same time. There were significant improvements in overall nocturnal quality of life, as well as well-being.
  
  
  CONCLUSIONS
  Treatment with insulin detemir for 6 months resulted in substantial benefits, including  reduced HbA(1c), FPG and body weight, and improvements in nocturnal quality of life, without increasing hypoglycaemia.
authors.affiliation: Oishi Clinic, 38-1 Karekicho, Fukakusa, Fushimi-ku, Kyoto 612-0875, Japan. oishi108@mbox.kyoto-inet.or.jp
authors.forename: M
authors.initials: M
authors.lastname: Oishi
authors.forename: N
authors.initials: N
authors.lastname: Abe
authors.forename: H
authors.initials: H
authors.lastname: Yokoyama
authors.forename: N
authors.initials: N
authors.lastname: Kuribayashi
authors.forename: O
authors.initials: O
authors.lastname: Tomonaga
authors.forename: K
authors.initials: K
authors.lastname: Matoba
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D015190:Blood Glucose Self-Monitoring; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007003:Hypoglycemia / Q000097:blood; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069057:Insulin Detemir; D007336:Insulin, Isophane / Q000627:therapeutic use*; D049528:Insulin, Long-Acting / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069057:Insulin Detemir; D007336:Insulin, Isophane; D049528:Insulin, Long-Acting